search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
AS I SEE IT


Trends in Colorectal Cancer Screening  BY CINDY YOUNG, RN, CASC


Colorectal cancer, a highly preventable and treatable disease, causes the second highest number of cancer deaths in the US, accord-


ing to the American Cancer Society. Colonoscopies can detect colorec- tal cancer in its early stages and pre- vent it from spreading. Unlike colo- noscopy, other screening options in the market allow patients to avoid going to a healthcare facility for test- ing. For example, the Cologuard test allows patients to collect a stool sam- ple at home and mail it to the lab in a pre-labeled box. Patients who are wary of the prep for and the invasive nature of colonoscopies often choose Cologuard, which detects colorec- tal neoplasia associated DNA mark- ers and occult hemoglobin in human stool. This test, however, comes with a potential problem. A patient with hemorrhoids might send a bloody sample and Cologuard would screen the sample positively for colorectal cancer. The patient would then have to go in for a colonoscopy to con- firm the screening and face insur- ance implications. We do see patients coming into our facility for a colo- noscopy because of a positive Colo- guard test.


Insurance covers Cologuard for colorectal cancer screening, but when a patient has to follow up the Cologuard test with a diagnostic colonoscopy, the screening colonos- copy gets coded as diagnostic. This leaves patients with higher out-of- pocket costs than if they were to have the traditional screening colo- noscopy in the first place.


The Cologuard test is not 100 per- cent accurate. According to the Gas- troenterology Consultants of San


8


Antonio website, Cologuard can detect 92 percent of cancers but only 42 percent of large precancerous pol- yps. Cologuard is better at detecting cancer than the fecal immunochemi- cal test (FIT)—92 percent versus 70 percent for FIT—but the false posi-


ASC FOCUS SEPTEMBER 2020 | ascfocus.org


tive rate is higher. Cologuard has a 12 percent false positive rate and that rate increases as people age, accord- ing to the company’s website. Our Surgery Center of Farming-


ton offers colonoscopy screening with two options that help patients


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30